Abstract
Hepatitis C virus (HCV) testing is recommended for all adults 18 years and older to increase identification of those with infection and facilitate prompt referral for curative antiviral therapy. While critical to promote elimination, this strategy excludes a key demographic group who are clearly at risk of undetected HCV infection and who could benefit from early treatment: adolescents. In this paper, we review the available data on the burden of HCV and the close association with injection drug use, discuss the rationale of universal testing in adolescents and, finally, present data from a quality improvement project implementing HCV testing into routine adolescent health visits.
Original language | English (US) |
---|---|
Pages (from-to) | S166-S170 |
Journal | Journal of the Pediatric Infectious Diseases Society |
Volume | 13 |
DOIs | |
State | Published - Dec 1 2024 |
Funding
Potential conflicts of interest . RJ: Research funding from CDC, NIH, AHRQ, GSK; Consultant for AstraZeneca, Seqirus, Sanofi and Gilead; Royalties from UptoDate; Editorial stipend from PIDS. All other authors: No reported conflicts.
Keywords
- adolescents
- hepatitis C virus
- screening
- testing
ASJC Scopus subject areas
- General Medicine